<DOC>
	<DOCNO>NCT00080444</DOCNO>
	<brief_summary>This study conduct demonstrate aprepitant ( MK-0869 ) prevent nausea vomit caused emetogenic cancer chemotherapy adolescent participant . Participants treat emetogenic cancer chemotherapy include either cisplatin , cyclophosphamide , carboplatin , participant experience nausea and/or vomit treat previously administer chemotherapy regimen plan repeat enrolled study . In double-blind Part 1 study , enrol participant randomize receive either aprepitant standard therapy . In Part 2 study , enrol participant receive open-label aprepitant .</brief_summary>
	<brief_title>Study Aprepitant ( MK-0869 ) Chemotherapy-Induced Nausea Vomiting ( CINV ) Adolescent Participants ( MK-0869-097 )</brief_title>
	<detailed_description>The duration treatment first 4 day one 28-day cycle ( Cycle 1 ) . Participants successfully complete Cycle 1 may eligible participate 9 subsequent optional , open-label , 28-day cycle .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Cycle 1 : Participant treat emetogenic chemotherapy regimen include either cisplatin , cyclophosphamide , carboplatin , document malignancy . OR Participant tolerate previously administer chemotherapy regimen , document malignancy , secondary nausea and/or vomit plan repeat . Cycle 1 : Participant Karnofsky score ≥60 Cycle 1 : Participant predict life expectancy ≥3 month Cycle 1 : Participant receive stem cell rescue therapy conjunction course chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>